EYENOVIA Raises $30M in Public Offering
Ticker: HYPD · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: public-offering, financing, pharmaceutical
TL;DR
EYENOVIA closed a $30M stock offering at $10/share on April 8, 2024.
AI Summary
On April 8, 2024, EYENOVIA, INC. announced the closing of its previously announced underwritten public offering. The company successfully raised approximately $30.0 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. This offering involved the sale of 3,000,000 shares of common stock at a price of $10.00 per share.
Why It Matters
The capital raised will provide EYENOVIA with additional resources to fund its operations and strategic initiatives, potentially accelerating its growth and product development in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Public offerings can dilute existing shareholders and the success of the company depends on the effective use of the raised capital.
Key Numbers
- $30.0M — Gross Proceeds (Funds raised from the public offering)
- 3,000,000 — Shares Sold (Quantity of common stock issued in the offering)
- $10.00 — Price Per Share (The price at which each share was sold)
Key Players & Entities
- EYENOVIA, INC. (company) — Registrant
- April 8, 2024 (date) — Closing date of the offering
- $30.0 million (dollar_amount) — Gross proceeds from the offering
- 3,000,000 (dollar_amount) — Number of shares sold
- $10.00 (dollar_amount) — Price per share
FAQ
What was the total amount of gross proceeds raised by EYENOVIA, INC. from the public offering?
EYENOVIA, INC. raised approximately $30.0 million in gross proceeds from the underwritten public offering.
When did EYENOVIA, INC. announce the closing of its public offering?
The closing of the underwritten public offering was announced on April 8, 2024.
How many shares of common stock were sold in the offering?
The company sold 3,000,000 shares of common stock in the offering.
What was the price per share for the common stock sold in the offering?
The common stock was sold at a price of $10.00 per share.
What are the estimated expenses to be deducted from the gross proceeds?
The filing states that gross proceeds are before deducting underwriting discounts and commissions and other offering expenses, but does not provide a specific dollar amount for these deductions.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-04-08 17:23:57
Key Financial Figures
- $0.0001 — h registered) Common stock, par value $0.0001 per share EYEN The Nasdaq Stock Mar
Filing Documents
- tm2411290d1_8k.htm (8-K) — 23KB
- 0001104659-24-044804.txt ( ) — 191KB
- eyen-20240408.xsd (EX-101.SCH) — 3KB
- eyen-20240408_lab.xml (EX-101.LAB) — 33KB
- eyen-20240408_pre.xml (EX-101.PRE) — 22KB
- tm2411290d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On April 8, 2024, Eyenovia, Inc. (the "Company") notified Leerink Partners LLC (f/k/a SVB Leerink LLC) ("Leerink Partners") that it was suspending its use of and terminating the prospectus supplement (the "ATM Prospectus Supplement"), related to the potential issuance from time to time of the Company's common stock pursuant to the Sales Agreement, dated December 14, 2021, by and between the Company and Leerink Partners (the "Sales Agreement"). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus Supplement, the Sales Agreement remains in full force and effect. Also on April 8, 2024, the Company announced by way of press release its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: April 8, 2024 /s/ John Gandolfo John Gandolfo Chief Financial Officer